Urine Biomarker for Colon Cancer?
March 2, 2012 | Melissa Marino
About half of colorectal tumors express elevated levels of COX-2, the key enzyme responsible for generating prostaglandins that promote cancer development. Prostaglandin E2 (PGE2) is likely the primary mediator of most of COX-2’s tumor-promoting effects, and the PGE2 metabolite, PGE-M, can be measured noninvasively in urine.
To assess the utility of PGE-M as a biomarker of colon cancer risk, Martha Shrubsole, Ph.D., and colleagues compared levels of PGE-M in the urine of patients with colorectal adenomas (precancerous lesions) versus controls.
In the February issue of Cancer Prevention Research, the investigators report that high levels of PGE-M in the urine was associated with increased risk of advanced or multiple adenomas, particularly among women. However, levels of PGE-M were not increased in patients with a less aggressive type of adenoma (single small tubular adenomas), suggesting that measuring urinary PGE-M may offer a way to distinguish which colon adenomas are more clinically significant.
The research was supported by grants from the National Cancer Institute.
No comments yet.
Sorry, the comment form is closed at this time.